- Q4 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 06, 2024$2.48 (-19.48%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2023$1.81 (-8.84%)Earnings
- Q2 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 08, 2023$2.58 (+3.61%)Earnings
- Q1 2023 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 09, 2023$2.73 (+13.75%)Earnings
- Q4 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 08, 2023$1.35 (-11.76%)Earnings
- Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Q3 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 09, 2022$1.48 (-1.33%)Earnings
- Xeris Biopharma Holdings Inc XP-8121 Call TranscriptOct 20, 2022
- Q2 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptAug 10, 2022$1.93 (+13.53%)Earnings
- Q1 2022 Xeris Biopharma Holdings Inc Earnings Call TranscriptMay 11, 2022$1.64 (-8.38%)Earnings
- Q4 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptMar 10, 2022$2.62 (+6.07%)Earnings
- Q3 2021 Xeris Biopharma Holdings Inc Earnings Call TranscriptNov 10, 2021$1.9 (-3.06%)Earnings
Q3 2021 Xeris Biopharma Holdings Inc Earnings Call Transcript
Good morning, and welcome to Xeris' Third Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast. A press release with the company's third quarter financial results was issued earlier this morning and can be found on our website. We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. Paul will provide opening remarks, Steve will provide details on our financial results, and then we will open up the call for Q&A. We will also be taking questions through the chat function of the webcast portal.
Before we begin, I would like to remind you that this call will contain forward-looking statements concerning the impact of COVID-19 on Xeris' business practices, Xeris' future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy and performance, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)